American Society of Hypertension Self-Assessment Guide
Treatment: Recent Clinical Trials

https://doi.org/10.1016/j.jash.2014.08.006Get rights and content

Section snippets

The Hypertension in the Very Elderly Trial (HYVET)

HYVET evaluated the usefulness of antihypertensive therapy versus placebo in individuals >80 years of age with a baseline systolic blood pressure (SBP) ≥160 mm Hg. The initial protocol required concurrent elevation in diastolic blood pressure (DBP; 90–109 mm Hg); a protocol amendment approved during the recruitment phase allowed inclusion of patients with isolated systolic hypertension. Subjects were randomized to receive the diuretic, indapamide (sustained–release) 1.5 mg/d or placebo. The

The Action to Control Cardiovascular Disease in Diabetes (ACCORD)

ACCORD was a prospective clinical endpoint study that randomized ‘high–risk’ participants with diabetes at 77 clinical sites in North America to receive either intensive or standard glycemic control (NEJM 2008;358:2545-2559). To be included in ACCORD, patients had to have had stable adult–onset diabetes for at least 3 months, had a glycohemoglobin of at least 7.5% but not more than 11%, be at least 40 years of age with established cardiovascular (CV) disease or at least 55 years of age with

The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

ONTARGET was an industry–sponsored, prospective, international, double–blind, randomized, clinical outcomes trial. Eligible patients (n = 29,019) from 40 countries had to have either coronary artery disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus with evidence of end–organ damage. Exclusion criteria were a history of heart failure, significant renal dysfunction, or previous intolerance to ACE inhibitor or angiotensin receptor blocker (ARB) therapy. Initially

Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH)

The JNC 7 report recommends physicians consider initiating therapy with two drugs, either as separate prescriptions or in fixed–dose combinations, when BP is >20 mm Hg above SBP goal or >10 mm Hg above DBP goal. It further suggests that one of these drugs should be a thiazide diuretic. The ACCOMPLISH trial was the first hypertension trial to compare single pill, fixed–dose combination therapies. A superiority trial supported by industry, it was based on the hypothesis that therapy with a

First page preview

First page preview
Click to open first page preview

References (0)

Cited by (0)

This article is part of the American Society of Hypertension Self-Assessment Guide series. For other articles in this series, visit the JASH home page at www.ashjournal.com.

View full text